SolasCure Limited
SolasCure is a biotech company dedicated to transforming chronic wound care through innovative, evidence-based solutions. Their mission is to develop effective, safe, and easy-to-use treatments that significantly improve patient outcomes and reduce healthcare costs. They focus on enzymatic debridement and wound healing technologies, notably their Aurase Wound Gel containing a recombinant enzyme cloned from maggots, which aims to support faster and more effective wound cleaning and healing.
Industries
Nr. of Employees
small (1-50)
SolasCure Limited
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
Enzymatic debridement hydrogel (recombinant proteolytic enzyme)
A hydrogel formulation containing a recombinant proteolytic enzyme cloned from medical maggot saliva, developed to debride chronic wounds, reduce biofilm/bioburden, and promote wound bed preparation and healing with pH-dependent activity and compatibility with standard dressing changes.
Enzymatic debridement hydrogel (recombinant proteolytic enzyme)
A hydrogel formulation containing a recombinant proteolytic enzyme cloned from medical maggot saliva, developed to debride chronic wounds, reduce biofilm/bioburden, and promote wound bed preparation and healing with pH-dependent activity and compatibility with standard dressing changes.
Services
Clinical trial design and execution (early-phase)
Design and conduct of Phase IIa safety and proof-of-concept studies for topical biologic wound therapies across multiple international centres.
Preclinical testing and toxicology studies
In vitro and in vivo efficacy testing and toxicology programmes to support regulatory filings and clinical translation.
Formulation optimisation and stability testing
Optimisation of hydrogel matrices for ambient-temperature stability and controlled enzyme release appropriate for community and home use.
Regulatory strategy and submission support
Preparation and management of regulatory interactions and filings to national agencies to support investigational use of a novel biologic/combination product.
Quality systems implementation and auditing
Implementation of clinical quality systems, site and vendor auditing, and maintenance of QA processes for clinical and preclinical programmes.
Clinical trial design and execution (early-phase)
Design and conduct of Phase IIa safety and proof-of-concept studies for topical biologic wound therapies across multiple international centres.
Preclinical testing and toxicology studies
In vitro and in vivo efficacy testing and toxicology programmes to support regulatory filings and clinical translation.
Formulation optimisation and stability testing
Optimisation of hydrogel matrices for ambient-temperature stability and controlled enzyme release appropriate for community and home use.
Regulatory strategy and submission support
Preparation and management of regulatory interactions and filings to national agencies to support investigational use of a novel biologic/combination product.
Quality systems implementation and auditing
Implementation of clinical quality systems, site and vendor auditing, and maintenance of QA processes for clinical and preclinical programmes.
Expertise Areas
- Chronic wound therapeutics
- Enzymatic debridement
- Hydrogel formulation for topical biologics
- Preclinical safety and toxicology
Key Technologies
- Recombinant enzyme expression
- Proteolytic/fibrinolytic enzyme therapeutics
- Hydrogel delivery systems
- Biomimetic therapeutic design